NCT05653635RecruitingPhase 2
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 28 Nov 2022
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Sept 2028
- Lead sponsor
- Centre Paul Strauss
- Diseases
- Glioblastoma
- NCT number
- NCT05653635
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 54
- From 1 Mar 2026 to the primary completion date, 1 Sept 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient with contraindication to MRI or PET
- Glioblastomatose
- Pregnancy or breastfeeding
- Patient that do not understand French
- Patient without affiliation to the national or local social security
- Patients not able to comply to the protocol assessments for geographic, social or psychological reasons
- Minor or patients placed under guardianship or supervision
- Patients deprived of liberty
- Patients placed under judicial protection
- Patients that are not able to express their consent
Who the study is looking for
- Age \> 18 years
- Glioblastoma, World Health Organization (WHO) grade IV, histologically proven
- Performance status 0, 1 or 2
- Neurological status ≥ 2
- Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)
- Radiological proven recurrence according to 1 and 2 criteria, Wen et al
- Remaining node after partial surgery post-recurrence
- 1 to 3 recurrence site(s) \< 35 mm in wide axis and separated by at least 5 mm
- Volume of each lesion \< 35 mL
- Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk \> 10 mm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU de Nancy Coordinator of this site? Confirm its status | Nancy | France | Not yet recruiting |
| Centre Paul Strauss Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.